Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5628307 | 0.93 | PTGER1 (0.46) | RAB9APTP4A3MAPTKMT2AMEN1 | |
| SCHEMBL6169074 | 0.86 | ERN1 (0.54) | RAB9AMAPTKMT2AMEN1HTT | |
| SCHEMBL5628445 | 0.82 | MRGPRX4 (0.51) | SMN1; SMN2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL14774805 | 0.81 | PTGER1 (0.52) | MAPTPTGER1MRGPRX4 | |
| SCHEMBL6234719 | 0.80 | DHODH (0.50) | RAB9APTP4A3DHODHSMN1; SMN2MAPT | |
| SCHEMBL6232024 | 0.77 | AR (0.50) | RAB9APTP4A3SMN1; SMN2MAPTKMT2A | |
| SCHEMBL5627381 | 0.77 | PTGER1 (0.55) | KMT2AMEN1ALDH1A1PTGER1 | |
| SCHEMBL18601076 | 0.77 | KMT2A (0.50) | RAB9APTP4A3SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2284712 | 0.76 | ENPP2 (0.54) | KMT2AALDH1A1MRGPRX4 | |
| SCHEMBL6685562 | 0.76 | ALDH1A1 (0.57) | RAB9ASMN1; SMN2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| CN-101896486-A | Spiroindolinone derivatives | HOFFMANN LA ROCHE | 2010-11-24 | — | — | CN | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | RAB9A 447/4885PTP4A3 1389/4885DHODH 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.